Humanin vs VIP
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Humanin is a mitochondria-derived peptide (MDP) encoded in the 16S rRNA region of the mitochondrial genome. It protects neurons and other cells from apoptosis, improves insulin sensitivity, and declines significantly with age. HNG (S14G-Humanin) is a synthetic analog with 1000x greater potency.
- VIP is a 28-amino acid neuropeptide with profound anti-inflammatory, vasodilatory, and immunomodulatory effects. It plays a critical role in gut motility, circadian rhythm, and immune tolerance. Used therapeutically for CIRS (Chronic Inflammatory Response Syndrome), MCAS, and inflammatory conditions.
- Half-Life
- ~4–8 hours (HNG)
- ~2 minutes in plasma (rapidly degraded by peptidases); intranasal delivery may extend local CNS effects
- Admin Route
- SubQ
- Intranasal, SubQ, IV
- Research
- —
- —
- Typical Dose
- 2–8 mg
- 50 mcg (4 sprays of 12.5 mcg each)
- Frequency
- 3–5 times per week
- 4x daily
- Key Benefits
- Neuroprotection against amyloid-beta toxicity (Alzheimer's relevance)
- Inhibits cellular apoptosis
- Improves insulin sensitivity
- Reduces cardiovascular risk markers
- Anti-inflammatory effects
- Correlates with longevity in centenarian studies
- Protects against ischemic injury
- Potential cancer cell apoptosis sensitization
- Potent anti-inflammatory for CIRS and mold illness
- Improves pulmonary hypertension symptoms
- Regulates gut motility and IBS symptoms
- Modulates circadian rhythm and sleep quality
- Reduces mast cell activation (MCAS)
- Improves cognitive function in neuroinflammatory conditions
- Vasodilatory — reduces vascular resistance
- Side Effects
- Injection site irritation
- Limited human safety data available
- Facial flushing (transient, intranasal)
- Mild nausea
- Headache at initiation
- Hypotension at high doses
- +1 more
- Stacks With
- —
- —